ASH 2018 | JCAR017 for relapsed/refractory CLL

Tanya Siddiqi

Tanya Siddiqi, MD, of the City of Hope, Duarte, CA., discusses the results of the TRANSCEND CLL-004 (NCT03331198) trial investigating the efficacy and safety of the anti-CD19 CAR T-cell product JCAR017 [(lisocabtagene maraleucel (liso-cel)] for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Siddiqi describes the positive response rates witnessed in the trial.

Share this video